Skip to main content

Aardvark Therapeutics, Inc.

AARD
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001774857

In the last 90 days, Aardvark Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 71 institutions reported holding it in 13F filings for Q2 2026, worth $55.0M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Aardvark Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
1 filing
1 insider, $395.0K in total
Insiders trading
1
Net value
−$395.0K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Aardvark Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Aardvark Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Sun NelsonSee Remarks35,475Sep 11, 20263
Chi JeffreyDirector133,364IndirectAug 21, 20261
Graf Susan EDirector–Aug 21, 20261
Baynes Roy D.Director–Aug 21, 20261
Tong Victor Edward JrDirector–Aug 21, 20261
Lee Tien-LiChief Executive Officer1,551,613Feb 11, 20263
Jaiman ManasiChief Medical Officer–Feb 11, 20261
Jones BryanChief Operating Officer1,250Oct 16, 20251
Cui Xiangmin10% Owner958,412IndirectFeb 19, 20250
Decheng Capital Global Life Sciences Fund IV, L.P.10% Owner958,412IndirectFeb 19, 20250
Decheng Capital Management IV (Cayman), LLC10% Owner958,412IndirectFeb 19, 20250
Decheng Capital Global Healthcare Fund (Master), LP10% Owner958,412IndirectFeb 19, 20250
Decheng Capital Global Healthcare GP, LLC10% Owner958,412IndirectFeb 19, 20250
Cormorant Asset Management, LPOther: Former 10% Owner987,689IndirectFeb 19, 20250
Chen BihuaOther: Former 10% Owner987,689IndirectFeb 19, 20250
Vickers Venture Fund VI Pte Ltd10% Owner2,050,902IndirectFeb 19, 20250

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 11, 2026 (view filing)8:14 PM ETSep 10-111 daySun NelsonSee RemarksSSaleCommon Stock, par value $0.00001 per share−76.8K$5.15−$395.0K−68.4%35.5K after2 lots10b5-1
Dec 12, 2025 (view filing)Dec 111 daySun NelsonChief Financial OfficerPPurchase+3.00K$14.40+$43.2K+2.8%108.5K after
Dec 12, 2025 (view filing)Dec 111 dayLee Tien-LiChief Executive OfficerPPurchase+7.00K$14.49+$101.4K+0.5%1.55M after
Sep 16, 2025 (view filing)Sep 151 dayLee Tien-LiChief Executive OfficerPPurchase+10.0K$9.66+$96.6K+0.7%1.54M after2 lots
Sep 12, 2025 (view filing)Sep 10-122 daysLee Tien-LiChief Executive OfficerPPurchase+20.0K$8.03+$160.6K+1.3%1.53M after3 lots
Sep 10, 2025 (view filing)Sep 91 daySun NelsonChief Financial OfficerPPurchase+6.00K$8.07+$48.4K+6.0%105.5K after
Feb 19, 2025 (view filing)5:44 PM ETFeb 145 daysCui Xiangmin and 4 others10% OwnerPPurchase+1.25M$16.00+$20.0MNew position958.4K after2 lots
Feb 19, 2025 (view filing)4:02 PM ETFeb 145 daysCormorant Asset Management, LP and 1 otherOther: Former 10% OwnerPPurchase+187.5K$16.00+$3.00M+23.4%987.7K after
Feb 19, 2025 (view filing)Feb 145 daysLee Tien-LiChief Executive OfficerPPurchase+16.5K$16.00+$264.7K+1.1%1.50M after
Feb 19, 2025 (view filing)Feb 145 daysSun NelsonChief Financial OfficerPPurchase+10.0K$16.00+$160.0K+11.2%99.5K after